Test Price
2,800 AED✅ Home Collection Available
SCN1A Gene (Early Infantile Epileptic Encephalopathy Type 6) Genetic Test in UAE | 2,800 AED | DHA Licensed
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified NGS processing with Sanger validation.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test counselling by a consultant medical geneticist, scheduled within 48 hours of result release.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SCN1A gene NGS test analyzes the entire coding region and flanking intronic sequences using next-generation sequencing (Illumina® platform) to detect pathogenic variants associated with early infantile epileptic encephalopathy type 6 (Dravet syndrome) and related SCN1A channelopathies. All clinically significant variants are confirmed by Sanger sequencing. This comprehensive analysis achieves 99.9% analytical sensitivity and specificity.
| Feature | Our Test (DHA‑Licensed) | Closest Alternative |
|---|---|---|
| Precision | Full gene NGS coverage (exons + flanking regions) with 99.9% analytical sensitivity | Single‑site testing or limited panel with lower resolution |
| Methodology | Illumina® NGS with Sanger validation of pathogenic variants | Sanger sequencing of selected exons only (incomplete analysis) |
| Turnaround Time | 3–4 Weeks with optional STAT reporting | 4–6 Weeks, no accelerated option |
| Sample Types | Blood (EDTA), Extracted DNA, or FTA Card – one drop sufficient | Often requires fresh blood only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh — Consultant Medical Genetics (DHA Registration ID: 9294403) shares:
“A pathogenic SCN1A variant provides a definitive molecular diagnosis, but it must always be interpreted in the full context of seizure semiology, developmental trajectory, and EEG patterns. This genetic clarity guides tailored antiseizure therapy and family counselling, yet compassionate clinical care remains irreplaceable. Never adjust medications based solely on the genetic report.”
Advisory – Medication & Clinical Precautions
Do not discontinue or modify any prescribed antiepileptic drug (e.g., valproate, clobazam, stiripentol) without direct consultation with your child’s neurologist. Abrupt cessation can provoke status epilepticus, which is a medical emergency. The genetic test result is intended to inform, not replace, your current treatment plan.
Exclusion Criteria & Emergency Red Flags
- Exclusion for home collection: Active febrile illness or uncontrolled seizures at the time of phlebotomy – the child must first be stabilised.
- Seek emergency care if: a seizure lasts longer than 5 minutes, clusters occur, consciousness does not return, or breathing becomes laboured after a convulsion. Go to the nearest emergency department immediately.
- Mandatory consent: Written informed consent from a legal guardian is required prior to sample collection, per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What does a positive SCN1A mutation mean for my child’s diagnosis?
A pathogenic SCN1A variant confirms a genetic diagnosis of Dravet syndrome or an SCN1A‑related epileptic encephalopathy. This result guides precision therapy selection (e.g., avoiding sodium channel blockers, using valproate, clobazam, or stiripentol) and provides a prognosis framework for families.
2. Can this test be performed on a newborn or infant?
Yes, the test requires only a small blood sample (one drop on an FTA card or 2 mL EDTA blood) and is validated for all ages, including neonates. Our phlebotomists follow strict paediatric protocols approved by the Dubai Health Authority.
3. How quickly can I receive results and genetic counselling?
Standard turnaround time is 3–4 weeks. An optional STAT (expedited) report is available upon request. After result release, a complimentary 20‑minute tele-counselling session with our consultant medical geneticist is arranged within 48 hours to explain findings and answer your questions.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Legal Compliance
This testing service operates under the auspices of DNA Labs UAE, DHA Facility License No. 1143. All personal and genetic data is processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic information is stored on UAE‑based secure servers with encrypted access. Pre‑ and post‑test genetic counselling is included in the listed price as mandated by DHA standards. Laboratory processes are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | SCN1A Gene (Early Infantile Epileptic Encephalopathy Type 6) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (STAT option available) |
| Sample Type / Matrix | Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Validation |
| ICD-10-CM Code | G40.3 |
| LOINC Code | 21680-2 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians